PMID- 11823970
OWN - NLM
STAT- MEDLINE
DCOM- 20020221
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 33
IP  - 1
DP  - 2002 Jan
TI  - Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a 
      comparative study of immunohistochemistry and fluorescence in situ hybridization 
      of formalin-fixed, paraffin-embedded tissues.
PG  - 21-8
AB  - We evaluated 173 consecutive breast carcinomas for c-erbB-2 using a combination 
      of immunohistochemistry (IHC) with a commercial polyclonal antibody (Nitirei) and 
      dual-color fluorescence in situ hybridization (FISH) using the c-erbB-2-specific 
      probe and the chromosome 17 centromere-specific probe from Vysis (Downers Grove, 
      IL) and compared the results with the histologic characteristics of intraductal 
      spread, cancer invasion, and intratumoral heterogeneity. With correction for 
      chromosome 17 copy number, c-erbB-2 amplification was observed in 26 tumors 
      (13.5%): high-level amplification in 23 tumors, and low-level amplification in 3. 
      The gene amplification was positively correlated with c-erbB-2 protein 
      overexpression, defined as 2+ or 3+ immunostaining, on a case-by-case basis (P < 
      .000001). All 3+ immunostaining tumors (19 tumors) showed high-level 
      amplification, although gene amplification was found in only 5 of 27 2+ 
      immunostaining tumors. Although the rates of overexpression and gene 
      amplification did not differ in ductal carcinomas in situ and invasive carcinomas 
      (P = .46 and .53, respectively), they were significantly higher in invasive 
      carcinomas with intraductal spreading (P < .0001). Intratumoral heterogeneity of 
      c-erbB-2 amplification was found in only 1 case; however, in 17 invasive 
      carcinomas, intraductal components expressed c-erbB-2 more intensely than 
      invasive components. We conclude that in breast carcinomas, c-erbB-2 
      overexpression occurs mostly in tumors with high-level gene amplification, and 
      such overexpression appears to endow carcinoma cells with the capacity for 
      intraductal spreading. The best method for detecting breast carcinomas with 
      c-erbB-2 aberrations using archival tissues is to screen cases by IHC; however, 
      follow-up FISH assays are indispensable for excluding false-positive results.
CI  - Copyright 2002 by W.B. Saunders Company
FAU - Kobayashi, Masako
AU  - Kobayashi M
AD  - Department of Molecular and Cellular Pathology, Graduate School of Medical 
      Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
FAU - Ooi, Akishi
AU  - Ooi A
FAU - Oda, Yoshio
AU  - Oda Y
FAU - Nakanishi, Isao
AU  - Nakanishi I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 1HG84L3525 (Formaldehyde)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Intraductal, Noninfiltrating/*genetics/metabolism/pathology
MH  - Female
MH  - Formaldehyde
MH  - Gene Amplification/*physiology
MH  - Gene Dosage
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Paraffin Embedding
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Tissue Fixation
EDAT- 2002/02/02 10:00
MHDA- 2002/02/22 10:01
CRDT- 2002/02/02 10:00
PHST- 2002/02/02 10:00 [pubmed]
PHST- 2002/02/22 10:01 [medline]
PHST- 2002/02/02 10:00 [entrez]
AID - S0046817702741804 [pii]
AID - 10.1053/hupa.2002.30185 [doi]
PST - ppublish
SO  - Hum Pathol. 2002 Jan;33(1):21-8. doi: 10.1053/hupa.2002.30185.